Hyderabad: Biological E to invest ₹1,800 crore in Genome Valley, to create over 2,500 jobs

The Telangana government in its statement said that Hyderabad accounts for one third of global vaccine production with a capacity of about nine billion doses per annum.

‘Vaccine Capital of the World’

“This investment from Biological E will enhance the capacity by five billion doses, increasing the cumulative capacity to about 14 billion doses each year, further consolidating the leadership of Hyderabad in vaccines,” the statement said.

“Hyderabad is already known as the ‘Vaccine Capital of the World’ and this expansion further accelerates our strength to serve the world with live saving vaccines,” KTR said.

Biological E said the investment will be focused on manufacturing of the Janssen Covid vaccine, MR vaccine, PCV vaccine, Typhoid vaccine, Tetanus toxide Ampoules, IPV vaccine and Pertussis vaccine, biological APIs and formulations, speciality generic injectables, as also enhancing R&D activities.

The cumulative investment will be of ₹1,801 crore and the facility is expected to employ 2,518 people.

Biological E has secured funding from the International Development Finance Corporation (DFC) to the tune of $50 million to expand the company’s capacity to produce Covid-19 vaccines.

It has developed one the indigenous vaccines for Covid-19 in the country — Corbevax. The vaccine has received the nod from the Drugs Controller General of India (DCGI) for emergency-use authorisation for the 5 to 12 years age group.